Skip to main content
PMC home page
Postgraduate Medical Journal logoLink to Postgraduate Medical Journal
. 1990 Nov;66(781):918–922. doi: 10.1136/pgmj.66.781.918

Immobilization-related hypercalcaemia--a possible novel mechanism and response to pamidronate.

S J Gallacher 1, S H Ralston 1, F J Dryburgh 1, F C Logue 1, B F Allam 1, B F Boyce 1, I T Boyle 1
PMCID: PMC2429738  PMID: 2267202

Abstract

Immobilization-related hypercalcaemia is an uncommon but important condition being associated not infrequently with both urolithiasis and osteoporosis. In this study 5 patients who had been immobilized for a mean of 3 months and had a mean adjusted serum calcium of 3.15 mmol/l were treated with doses of intravenous pamidronate ranging between 10 mg and 45 mg. All patients became normocalcaemic by day 3. Patients 1-3 mobilized shortly after treatment and remained normocalcaemic. In those patients who continued to be immobile hypercalcaemia recurred after an interval of several weeks. Retreatment with pamidronate again resulted in normocalcaemia. No side effects were noted with treatment. All of the patients studied had increased rates of bone resorption as shown by elevated urinary hydroxyproline/creatinine ratios (median:range) of 0.101:0.045-0.180 (normal less than 0.033) and elevated calcium/creatinine ratios of 2.50:0.69-3.63 (normal less than 0.50). None of the patients in this study had any of the usual risk factors for developing immobilization-related hypercalcaemia though all 5 patients had problems with significant sepsis which we postulate may have lead to cytokine release which in turn contributed to the development of hypercalcaemia. We conclude that pamidronate (at doses as low as 10 mg) is safe and effective in immobilization-related hypercalcaemia and suggest that sepsis should be added to the list of risk factors for development of this syndrome.

Full text

PDF
918

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Beastall G. H., McKellar N., Boyle I. T., Joffe S. N., Hutchison J. S., Boyce B. F., Gardner M. D., Bell M. A., Cowan R. A., Fogelman I. Pre-operative localisation of parathyroid tumours using neck vein catheterisation and radioimmunoassay for parathyroid hormone: the Glasgow experience. Scott Med J. 1983 Apr;28(2):146–152. doi: 10.1177/003693308302800210. [DOI] [PubMed] [Google Scholar]
  2. Cann C. E., Genant H. K., Young D. R. Comparison of vertebral and peripheral mineral losses in disuse osteoporosis in monkeys. Radiology. 1980 Feb;134(2):525–529. doi: 10.1148/radiology.134.2.6766220. [DOI] [PubMed] [Google Scholar]
  3. Carey D. E., Raisz L. G. Calcitonin therapy in prolonged immobilization hypercalcemia. Arch Phys Med Rehabil. 1985 Sep;66(9):640–644. [PubMed] [Google Scholar]
  4. Frijlink W. B., Bijvoet O. L., te Velde J., Heynen G. Treatment of Paget's disease with (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (A.P.D.). Lancet. 1979 Apr 14;1(8120):799–803. doi: 10.1016/s0140-6736(79)91318-7. [DOI] [PubMed] [Google Scholar]
  5. Gardner M. D., Dryburgh F. J., Fyffe J. A., Jenkins A. S. Predictive value of derived calcium figures based on the measurement of ionised calcium. Ann Clin Biochem. 1981 Mar;18(Pt 2):106–109. doi: 10.1177/000456328101800210. [DOI] [PubMed] [Google Scholar]
  6. Goverde B. C., Veenkamp F. J. Routine assay of total urinary hydroxyproline based on resin-catalysed hydrolysis. Clin Chim Acta. 1972 Oct;41:29–40. doi: 10.1016/0009-8981(72)90492-5. [DOI] [PubMed] [Google Scholar]
  7. Gurney H., Kefford R., Stuart-Harris R. Renal phosphate threshold and response to pamidronate in humoral hypercalcaemia of malignancy. Lancet. 1989 Jul 29;2(8657):241–244. doi: 10.1016/s0140-6736(89)90429-7. [DOI] [PubMed] [Google Scholar]
  8. HEANEY R. P. Radiocalcium metabolism in disuse osteoporosis in man. Am J Med. 1962 Aug;33:188–200. doi: 10.1016/0002-9343(62)90017-7. [DOI] [PubMed] [Google Scholar]
  9. Issekutz B., Jr, Blizzard J. J., Birkhead N. C., Rodahl K. Effect of prolonged bed rest on urinary calcium output. J Appl Physiol. 1966 May;21(3):1013–1020. doi: 10.1152/jappl.1966.21.3.1013. [DOI] [PubMed] [Google Scholar]
  10. Johnson R. A., Boyce B. F., Mundy G. R., Roodman G. D. Tumors producing human tumor necrosis factor induced hypercalcemia and osteoclastic bone resorption in nude mice. Endocrinology. 1989 Mar;124(3):1424–1427. doi: 10.1210/endo-124-3-1424. [DOI] [PubMed] [Google Scholar]
  11. LANDRY M., FLEISCH H. THE INFLUENCE OF IMMOBILISATION ON BONE FORMATION AS EVALUATED BY OSSEOUS INCORPORATION OF TETRACYCLINES. J Bone Joint Surg Br. 1964 Nov;46:764–771. [PubMed] [Google Scholar]
  12. McIntyre H. D., Cameron D. P., Urquhart S. M., Davies W. E. Immobilization hypercalcaemia responding to intravenous pamidronate sodium therapy. Postgrad Med J. 1989 Apr;65(762):244–246. doi: 10.1136/pgmj.65.762.244. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Peacock M., Robertson W. G., Nordin B. E. Relation between serum and urinary calcium with particular reference to parathyroid activity. Lancet. 1969 Feb 22;1(7591):384–386. doi: 10.1016/s0140-6736(69)91353-1. [DOI] [PubMed] [Google Scholar]
  14. Ralston S. H., Cowan R. A., Robertson A. G., Gardner M. D., Boyle I. T. Circulating vitamin D metabolites and hypercalcaemia of malignancy. Acta Endocrinol (Copenh) 1984 Aug;106(4):556–563. doi: 10.1530/acta.0.1060556. [DOI] [PubMed] [Google Scholar]
  15. Ralston S. H., Gallacher S. J., Patel U., Dryburgh F. J., Fraser W. D., Cowan R. A., Boyle I. T. Comparison of three intravenous bisphosphonates in cancer-associated hypercalcaemia. Lancet. 1989 Nov 18;2(8673):1180–1182. doi: 10.1016/s0140-6736(89)91791-1. [DOI] [PubMed] [Google Scholar]
  16. Rosen J. F., Wolin D. A., Finberg L. Immobilization hypercalcemia after single limb fractures in children and adolescents. Am J Dis Child. 1978 Jun;132(6):560–564. doi: 10.1001/archpedi.1978.02120310024004. [DOI] [PubMed] [Google Scholar]
  17. Sabatini M., Boyce B., Aufdemorte T., Bonewald L., Mundy G. R. Infusions of recombinant human interleukins 1 alpha and 1 beta cause hypercalcemia in normal mice. Proc Natl Acad Sci U S A. 1988 Jul;85(14):5235–5239. doi: 10.1073/pnas.85.14.5235. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Series J. J., Shapiro D., Cameron I., Smith J., Fraser W. D., Garden O. J., Shenkin A. Rapid, sensitive detection of plasma IL-1 by extraction and bioassay. J Immunol Methods. 1988 Apr 6;108(1-2):33–37. doi: 10.1016/0022-1759(88)90399-7. [DOI] [PubMed] [Google Scholar]
  19. Thiébaud D., Jaeger P., Jacquet A. F., Burckhardt P. Dose-response in the treatment of hypercalcemia of malignancy by a single infusion of the bisphosphonate AHPrBP. J Clin Oncol. 1988 May;6(5):762–768. doi: 10.1200/JCO.1988.6.5.762. [DOI] [PubMed] [Google Scholar]
  20. Tori J. A., Kewalramani L. S. Urolithiasis in children with spinal cord injury. Paraplegia. 1979 Feb;16(4):357–365. doi: 10.1038/sc.1978.68. [DOI] [PubMed] [Google Scholar]
  21. Yates A. J., Jones T. H., Mundy K. I., Hague R. V., Brown C. B., Guilland-Cumming D., Kanis J. A. Immobilisation hypercalcaemia in adults and treatment with clodronate. Br Med J (Clin Res Ed) 1984 Oct 27;289(6452):1111–1112. doi: 10.1136/bmj.289.6452.1111. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Postgraduate Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES